Citation Tools
PDFResponse
Ethical considerations for protecting the options of subjects in primary epidemic vaccine trials
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Ethical considerations for protecting the options of subjects in primary epidemic vaccine trials
Other content recommended for you
- The UPTAKE study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancy
- Covid-19: Vaccine trials need more transparency to enable scrutiny and earn public trust, say experts
- Ethical considerations for epidemic vaccine trials
- Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine research
- COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement
- Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial
- Vaccines for older adults
- Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial
- Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial
- Phase II meningococcal B vesicle vaccine trial in New Zealand infants